Galecto, Inc. (GLTO)
NASDAQ: GLTO · Real-Time Price · USD
3.230
-0.190 (-5.56%)
Mar 31, 2025, 1:22 PM EDT - Market open
Galecto Employees
Galecto had 5 employees as of December 31, 2024. The number of employees decreased by 8 or -61.54% compared to the previous year.
Employees
5
Change (1Y)
-8
Growth (1Y)
-61.54%
Revenue / Employee
n/a
Profits / Employee
-$4,287,800
Market Cap
4.27M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5 | -8 | -61.54% |
Dec 31, 2023 | 13 | -32 | -71.11% |
Dec 31, 2022 | 45 | 5 | 12.50% |
Dec 31, 2021 | 40 | 12 | 42.86% |
Dec 31, 2020 | 28 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GLTO News
- 11 days ago - Galecto Reports Full-Year 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Galecto to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Galecto Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 5 months ago - Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - GlobeNewsWire
- 6 months ago - Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines - GlobeNewsWire
- 7 months ago - Galecto Announces Reverse Stock Split - GlobeNewsWire
- 11 months ago - Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab - GlobeNewsWire
- 1 year ago - Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis - GlobeNewsWire